Justin Sun Announces Tron Will Launch Tokenized Shares in the Fourth Quarter! Here Are the Details

The second paragraph adds stock information, while the fifth, eighth, and ninth paragraphs provide additional details. Background information is supplemented in the sixth, seventh, tenth, and eleventh paragraphs. Reuters, October 8 – Pharmaceutical company Viatris (VTRS.O) will acquire Pacira BioSciences (PCRX.O) in an all-cash deal worth $1.65 billions, adding two non-opioid painkillers to its portfolio, the companies said on Thursday. Viatris will acquire Pacira at $36.50 per share, representing a 44.8% premium to the latest closing price. Pacira’s stock rose by 44% in premarket trading. Pacira’s non-opioid painkillers, Exparel and Zilretta, generated sales in 2025 of $575.1 millions and $116.6 millions respectively. Exparel is used to relieve acute pain after surgery, and Zilretta is used to treat pain associated with knee osteoarthritis. Viatris stated it expects to expand the reach of these products in selected target markets. Viatris CEO Scott Smith stated, “the addition of these medications creates a synergy with our rapid-acting meloxicam market opportunities, positioning us as a leader in non-opioid pain management.” The US Food and Drug Administration (FDA) is expected to make a decision by December 27 on the approval application for rapid-acting meloxicam for the treatment of moderate to severe acute pain. Viatris plans to finance the acquisition primarily with idle cash, and the remainder through short-term borrowing. The company noted the deal will have minimal impact on its total leverage ratio. In August, Viatris (link) raised its annual adjusted profit forecast, counting on strong brand drug sales and growth in the Chinese market. The pharmaceutical company had previously faced (link) production setbacks in its Indian operations, including a fire at its Nashik plant in western India and increased competition in the generic drug market, raising concerns about the resilience and growth of its core business. The company stated the transaction is expected to close by the end of 2026 and will immediately enhance Viatris’s financial guidance metrics. (For non-native English speakers, Reuters provides automated translations of its reports into several other languages. Since automated translations may contain errors or lack necessary context, Reuters does not guarantee their accuracy and provides them for convenience only. Reuters accepts no liability for any damage or loss caused by the use of automated translation.)

08:51 AM EDT, 10/08/2026 (MT Newswires) -- Acuity Brands (AYI) has an average rating of overweight and mean price target of $400.57, according to analysts polled by FactSet. (MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www.mtnewswires.com/contact-us)

On October 8, Pacira BioSciences (PCRX.O) shares rose 44% in pre-market trading to $36.30 as Viatris (VTRS.O) announced it will acquire Pacira BioSciences for $1.65 billion in cash, at a price of $36.50 per share. This offer represents a premium of approximately 44.8% over Pacira's last closing price of $25.20. The transaction will add Pacira’s non-opioid pain medications Exparel and Zilretta to Viatris’ product portfolio. Both parties expect the deal to be completed by the end of 2026. As of the previous trading day’s close, PCRX was down 2.6% year-to-date.

October 8 - Oil and gas producer Devon Energy (DVN.N) rose 2.65% in pre-market trading to $49.15. The company announced it would sell its Eagle Ford assets to Crescent Energy (CRGY.N) for $4.2 billions in cash. Devon's Eagle Ford assets include approximately 90,000 net acres in Texas, representing about 4% of its total oil equivalent production. This asset divestiture comes as the company, following its merger with Coterra Energy, faces investor pressure to streamline its asset portfolio and focus on its core Permian Basin business. The transaction is expected to be completed around the end of 2026. CRGY shares fell 2% to $13.20; the company also announced a $1 billions stock offering to raise funds for the DVN transaction. As of the previous trading day’s close, DVN shares had surged 30.71% year-to-date.